



Jackson, L., Woodward, M., & Coward, R. J. (2017). The molecular biology of pelvi-ureteric junction obstruction. *Pediatric Nephrology*, 1-19. <https://doi.org/10.1007/s00467-017-3629-0>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.1007/s00467-017-3629-0](https://doi.org/10.1007/s00467-017-3629-0)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Springer Link at <https://link.springer.com/article/10.1007%2Fs00467-017-3629-0#Ethics>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

# The molecular biology of pelvi-ureteric junction obstruction

Laura Jackson<sup>1,2</sup>  · Mark Woodward<sup>2</sup> · Richard J. Coward<sup>1,2</sup>

Received: 11 October 2016 / Revised: 16 February 2017 / Accepted: 17 February 2017  
© The Author(s) 2017. This article is published with open access at Springerlink.com

**Abstract** Over recent years routine ultrasound scanning has identified increasing numbers of neonates as having hydronephrosis and pelvi-ureteric junction obstruction (PUJO). This patient group presents a diagnostic and management challenge for paediatric nephrologists and urologists. In this review we consider the known molecular mechanisms underpinning PUJO and review the potential of utilising this information to develop novel therapeutics and diagnostic biomarkers to improve the care of children with this disorder.

**Keywords** Pelvi-ureteric junction obstruction · Aetiology · Molecular biology · Biomarker · Hydronephrosis

## Introduction

Antenatally detected hydronephrosis is a major clinical dilemma for paediatric nephrologists and urologists (incidence of 1 in 200) [1]. This condition has become more prevalent in recent years as antenatal scanning has become more sensitive and widely used. Approximately one in seven neonates with antenatally detected hydronephrosis has pelvi-ureteric junction obstruction (PUJO) [2–4], making PUJO one of the most common causes of congenital urinary tract obstruction, with

an incidence of one in 1000 to one in 2000 live births [3–5]. Interestingly, males are affected approximately threefold more frequently than females by this condition [4]. The reason for this difference is unknown.

Intrinsic obstruction due to an adynamic stenotic segment at the PUJ is the most common aetiology (75% of cases) [4], with failure of peristalsis producing an incomplete, functional obstruction. Other causes include: crossing vessels (20%), peripelvic fibrosis, abnormal ureteric insertion, fibroepithelial polyps and anatomical variants, such as retrocaval ureter, horseshoe and duplex kidneys [4, 6, 7].

The major challenge for clinicians is deciding which of these children, who are largely asymptomatic, require a pyeloplasty to relieve the obstruction. This is because two-thirds of children with PUJO do not sustain renal damage or need surgery, and their hydronephrosis spontaneously improves [8–10].

Currently, serial ultrasound and invasive isotope studies are performed to guide surgical management of PUJO [4]. However, the ability of these diagnostic modalities to accurately detect obstruction, identify children at risk of functional deterioration and predict the need for surgery is questionable. Additionally, there remains debate regarding the parameters which indicate clinically significant obstruction [9, 11–13].

In general a pyeloplasty is performed for [6]:

- differential renal function deterioration (differential function of <40% or a fall of >10% on serial MAG3 renograms)
- significant hydronephrosis with a renal pelvis anteroposterior diameter of >3 cm on ultrasound scan
- increasing hydronephrosis with an increasing anteroposterior diameter on serial ultrasound scan
- symptomatic children.

---

✉ Laura Jackson  
laura.jackson@bristol.ac.uk

<sup>1</sup> Bristol Renal Group, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol BS1 3NY, UK

<sup>2</sup> Bristol Royal Hospital for Children, Bristol, UK


Our current understanding of the natural history of PUJO as well as our ability to distinguish which children require surgery is inadequate. Available diagnostic tests cannot accurately discern between children with PUJO that will resolve spontaneously and those with PUJO that will persist, causing functional impairment. Consequently, despite radiological monitoring, there is a risk of loss of function in the affected kidney while the patient is under observation [14].

In this review we discuss the currently known molecular mechanisms underlying intrinsic PUJO and whether this information could contribute to the future development of novel therapies and diagnostic biomarkers.

### Anatomy of the upper urinary tract


The PUJ is a region of gradual transition from the funnel-shaped renal pelvis to the proximal ureter [15] (Fig. 1). It is a physiologic sphincter [16] that is characterised by prominent luminal folds with increased muscle thickness capable of creating a high-pressure zone to regulate urine flow. Similar to the adjacent renal pelvis and ureter, the PUJ comprises three main layers: the inner urothelium, middle smooth muscle and outer adventitia [15]. Smooth muscle contraction propels urine from the renal pelvis to the bladder [17], coordinated by submucosal and intra-muscular nerve plexi [18] and modulated by autonomic innervation involving a range of neurotransmitters that include acetylcholine, noradrenaline, substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y, vasoactive intestinal peptide and nitric oxide (NO) [17].

**Fig. 1** Diagrammatic representation of the pelvi-ureteric junction (PUJ). The gradual transition from the renal pelvis to the proximal ureter is illustrated as well as the increased mucosal folds and smooth muscle thickening in this region



### Embryology of the ureter and PUJ

Understanding the normal embryology of PUJ formation is vital when considering where development may proceed incorrectly in congenital abnormalities such as PUJO. The kidney develops from metanephric mesoderm as far along the nephron as the distal tubules. The collecting duct onwards, including the major and minor calyces, renal pelvis and ureter has a different embryological origin, arising from the ureteric bud [19, 20]. Thus, the PUJ does not represent an embryological fusion site, rather it is derived exclusively from the ureteric bud. The important molecular pathways that form the ureter and PUJ are shown in Fig. 2 and Table 1 [15, 26–28]. Briefly, the ureteric bud, consisting of a simple epithelial layer extending into loose mesenchyme, arises from the mesonephric duct during the fifth week of gestation in humans [26]. Epithelial cell proliferation and differentiation then results in the formation of the transitional epithelium. Epithelial paracrine and mesenchymal autocrine signalling stimulates the formation of smooth muscle cells from mesenchyme, which begins at 12 weeks of gestation in humans [26, 29]. Mouse models have implicated a number of signalling molecules in this process of proliferation, aggregation, differentiation and orientation of smooth muscle cells as they encircle the urothelial tube (Fig. 2, Table 1). A second phase of smooth muscle differentiation that particularly affects the renal pelvis and proximal ureter occurs in postnatal mice (equivalent to the second trimester of gestation in humans) and is regulated by calcineurin and angiotensin II signalling [30, 31].



**Fig. 2** Embryological signalling pathways of the PUI. The ureteric bud arises from the mesonephric duct and initially consists of only a simple epithelial layer extending into loose mesenchyme. Epithelial cell proliferation and differentiation to form transitional epithelium leads to luminal obliteration, which at the end of the embryonic period is corrected by physiologic recanalisation of the ureter. Epithelial paracrine and mesenchymal autocrine signalling stimulates the proliferation and differentiation of the mesenchyme into smooth muscle cells (SMC) which aggregate and orientate so as to encircle the epithelial tube. Specifically, the urothelium secretes SHH which activates the PDCH1 receptor on adjacent mesenchyme, thereby stimulating mesenchymal proliferation. Mesenchymal cells (MC) express TBX18, a T-box transcription factor, which enables the correct localisation and aggregation of the former around the urothelium. The mesenchymal cells also

express BMP4 which acts in an autocrine manner to upregulate TSHZ3 and MYODC. MYODC enables differentiation of SMC by increasing the transcription of genes encoding smooth muscle contractile proteins. DLGH1, expressed by the urothelium and SMC, is responsible for the correct orientation of SMC around the urothelial tube. In postnatal mice (equivalent to second trimester of gestation in humans), increased urine production matches the development of the renal pelvis and is accompanied by a second phase of muscle differentiation that particularly affects the renal pelvis and proximal ureter, regulated by calcineurin and angiotensin II signalling. The timeline refers to days of gestation (E embryonic day) in mouse models. MD Mesonephric duct, UB ureteric bud, MC mesenchymal cells. See Table 1 for description of factors active in the pathways involved in ureteric development

## Pathologic features of intrinsic PUJO

Inflammatory cell infiltration [32], varying degrees of fibrosis, excess collagen deposition [32–35] and abnormal muscle fibre arrangement [36] are present in human intrinsic PUJO obstruction. Both muscular hypertrophy/hyperplasia [32, 34, 37] and atrophy/hypoplasia [32, 36] are reported alongside depletion of nerves to the muscular layer [33]. These findings are noted when the PUJO is excised at pyeloplasty and therefore represent late features of PUJO obstruction (Fig. 3). Although the time course of PUJO disease progression is unknown in humans, genetic mouse models of hydronephrosis show abnormalities of peri-urothelial mesenchymal organisation as early as embryonic day (E) 12.5 (approximately equivalent to 35 days of gestation in humans) [24] and smooth muscle cell differentiation at E15.5 (approximately equivalent to 12 weeks of gestation in humans)

[23]. One week postnatally (approximately equivalent to humans at birth) mice with Id2 haploinsufficiency show smooth muscle irregularity and hypertrophy at the PUJO [38], features which are common to human PUJO. The possible mechanisms underlying this pathology are described later in this review.

## Modelling PUJO to understand its molecular biology

Adult and neonatal rodent models of complete and partial unilateral ureteric obstruction (UUO) have been extensively used to investigate the molecular biology of congenital obstructive nephropathy. Neonatal models are particularly helpful because rodent nephrogenesis continues for 1 week postnatally and nephron maturation over the subsequent week. Thus, at birth and 1 week of age, rodent kidney development is equivalent to humans at the second

**Table 1** Proteins/molecular pathways involved in ureteric development

Protein	Full protein name	Function	Reference
SHH	Sonic hedgehog	Morphogen which stimulates peri-urothelial mesenchymal cell proliferation and regulates timing of smooth muscle cell differentiation	[21]
PTCH1 receptor	Protein patched homolog 1	Receptor for SHH, functions as tumour suppressor when unbound	[21]
BMP4	Bone morphogenetic protein 4	Growth factor, necessary for smooth muscle cell differentiation and ureter morphogenesis	[22]
TSHZ3	Teashirt zinc finger homeobox 3	Transcription factor-like protein necessary for myocardin expression and ureteric smooth muscle cell differentiation	[23]
MYOCD	Myocardin	Transcriptional co-activator, necessary for expression of contractile proteins	[23]
TBX18	T Box protein 18	Transcription factor necessary for correct localisation and aggregation of smooth muscle cells around ureteric urothelium	[24]
DLGH1	Disks large homolog 1	Scaffolding protein, regulates smooth muscle cell orientation	[25]

trimester of gestation and birth, respectively [11]. This gives a window in which surgery can be performed on the animals to mimic in utero obstruction in humans. Adult obstructive models show a broadly similar pathologic progression to neonatal models with the exception that neonatal obstruction impedes normal maturation and growth of the kidney and leads to early nephron loss. The renal pathologic findings in neonatal and adult UJO models and the timescale of their development are presented in Fig. 4 [39–47].

A comprehensive review comparing neonatal models with human disease confirms their validity for investigating obstructive nephropathy and will not be further discussed in this review [48].


### Proposed molecular mechanisms underpinning PUJO

In the following subsections we highlight some of the molecular steps that may lead to the development of intrinsic PUJO and subsequent obstructive nephropathy. Data have been obtained from both adult and neonatal models of complete and partial ureteric obstruction alongside evaluation of tissue obtained at pyeloplasty for human PUJ obstruction.


#### Neurogenic factors

Light microscopy studies have revealed reduced innervation within the muscular layer of the PUJ in human specimens

**Fig. 3** Pathologic features of intrinsic PUJO. Reduced luminal mucosal folds, excess collagen deposition, depletion of nerves within the muscular layer, abnormal muscle fibre arrangement, inflammatory infiltrate and both muscle hypertrophy/hyperplasia and muscle atrophy/hypoplasia are seen at the PUJ in human PUJO



**Fig. 4** Pathologic features of rodent models of unilateral ureteric obstruction (UUO). Timeline of the development of renal pathogenic features in neonatal and adult models of UUO. CUUO Complete UUO, PUUO partial UUO



excised at pyeloplasty for PUJO [33]. This is associated with reduced expression of molecular markers, including glial cell line-derived neurotrophic factor (survival factor for neurons), protein gene product 9.5 (general neuronal marker), and nerve growth factor receptor protein, in the muscle layers of the stenotic PUJ compared to controls. Although it is speculated that these neuronal changes may contribute to the

pathogenesis of PUJO, there is as yet no evidence to confirm or refute this notion. Conflicting changes in synaptophysin (e.g. major synaptic vesicle protein p38) expression in terms of both amount (increased and decreased) and distribution (localisation to the nucleus) are reported in PUJO compared to controls and are of uncertain significance. S-100 (schwann cell marker) and neurofilament (neuronal protein) expression



are unchanged, demonstrating there is not a global reduction in neuronal components [34, 49].

## Myogenic factors

Together with increased smooth muscle cell apoptosis, phenotypic and cytoskeletal smooth muscle cell changes are seen in the human PUJ excised at pyeloplasty for PUJO. The stenotic PUJ shows significantly increased expression of smooth muscle myosin heavy chain isoforms 1 and 2 [37], as well as an

altered ratio of integrin (transmembrane signalling receptor) isoform expression compared to control samples [50]. The preferential expression of immature integrins in the stenotic PUJ [50] may indicate developmental delay of the smooth muscle cells, potentially contributing to their altered function and increased apoptosis in PUJO.

Supporting a myogenic cause of PUJO, transgenic mouse models targeting smooth muscle differentiation generate a PUJ phenotype with hydronephrosis secondary to functional obstruction (Table 2).

**Table 2** Evidence from animal and human studies of genes potentially involved in the pathogenesis of pelvi-ureteric junction obstruction

Gene	Full gene name	Animal	Features and mechanism	Human	Reference
<i>Ace</i>	Angiotensin converting enzyme	<i>Ace</i> <sup>-/-</sup> mice	Hydronephrosis, renal parenchymal atrophy		[51]
<i>Adamts-1</i>	A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 1	<i>Adamts</i> <sup>-1/-</sup> mice	PUJ obstruction, increased collagen at PUJ. Other urogenital anomalies.		[52]
<i>Agt</i>	Angiotensin	<i>Agt</i> <sup>-/-</sup> mice	Hydronephrosis, renal parenchymal atrophy,		[53]
<i>Agtr 1a/b</i>	Angiotensin II receptor type 1 (1a and 1b)	<i>Agtr</i> <sup>1-/-</sup> (1a and 1b) mice	Hydronephrosis in older mice, renal parenchymal atrophy, failure of renal pelvis development, ureteric smooth muscle hypoplasia and abnormal peristalsis		[31]
<i>Aqp2</i>	Aquaporin 2	<i>Aqp</i> <sup>2S256L/S256L</sup> CPH mice	Mutation in CPH mice prevents Aqp2 phosphorylation and normal trafficking. Hydronephrosis secondary to polyuria		[54]
<i>Calcineurin</i>	Calcineurin. Also known as Protein phosphatase 3 (ppp3)	<i>Pax3-Cre</i> <sup>T/+</sup> ; <i>Cnbl</i> <sup>flox/flox</sup> mice	Calcineurin inactivation in metanephric and ureteral mesenchyme giving hydronephrosis, abnormal pyeloureteral peristalsis with defective renal pelvis and smooth muscle development		[30]
<i>Id2</i>	Inhibitor of DNA binding 2	<i>Id2</i> <sup>-/-</sup> and <i>Id2</i> <sup>+/-</sup> mice	Hydronephrosis and PUJ development		[38]
<i>Nfia</i>	Nuclear factor I/A	<i>Nfia</i> <sup>+/-</sup> and <i>Nfia</i> <sup>-/-</sup> mice	Hydronephrosis, VUR, abnormal PUJ and VUJ development. CNS malformations.	<i>Nfia</i> <sup>+/-</sup> due to chromosomal translocation and deletion. VUR and CNS malformations.	[55]
<i>TBX18</i>	T-box transcription factor	<i>Tbx18</i> <sup>-/-</sup> mice	Hydronephrosis, short ureters, ureteric smooth muscle defects due to abnormal smooth muscle cell differentiation and localisation	Hispanic family with autosomal dominant CAKUT predominantly PUJO. Heterozygous truncating mutation (c.1010delG) of <i>Tbx18</i>	[24, 56]
<i>Tshz2</i> and <i>3</i>	Teashirt zinc finger family member 2 and 3	<i>Tshz3</i> <sup>-/-</sup> mice	Hydronephrosis with PUJ configuration, abnormal smooth muscle differentiation proximal ureter	<i>Tshz2/Tshz3</i> mutations not cause of PUJO in Albanian/Macedonian population	[57, 58]

CAKUT, Congenital anomalies of the kidney and urinary tract; CNS, central nervous system; CPH, congenital progressive hydronephrosis; PUJO, pelvi-ureteric junction obstruction; VUJ, vesico-ureteric junction; VUR, vesico-ureteric reflux

## Increased pressure, impeded blood supply and hypoxia

Obstructive hydronephrosis is associated with a doubling of renal pelvis pressure [16, 59–61]. The resultant increased intratubular hydrostatic pressure [62] stimulates the renopathogenic effects of obstruction via three proposed mechanisms, namely, (1) tubular ischaemia due to hypoperfusion, (2) pressure-induced mechanical stretch/compression of tubular cells and (3) altered urinary shear stress. The latter two mechanisms are likely to be the primary inducers of obstructive renal injury [48], causing dysregulation of many cytokines, growth factors, enzymes and cytoskeletal proteins (Table 3), resulting in early renal haemodynamic changes followed by structural and functional alterations to the entire nephron. Figure 5 highlights the major mechanisms of renal injury in PUJO.

Following a short initial increase in renal blood flow related to local vasodilator production [48], the intra-renal renin–angiotensin–aldosterone system (RAAS) is activated causing pre- and post-glomerular vasoconstriction and a resultant fall in renal blood flow (RBF), medullary oxygen tension and glomerular filtration rate (GFR) [11, 48, 64, 80, 88–90]. Proximal tubular hypoxia and necrosis in neonatal rats with UUO suggest that vasoconstriction causes segment-specific ischaemic injury [91]. Accordingly, angiotensin II receptor, type 1 (AT1 receptor) inhibition improves tubular function by increasing RBF and GFR [92].

Reduced urine production and continuing urine drainage by venous and lymphatic systems together with tubular and renal pelvis dilatation result in a subsequent decline in renal pelvic pressure [48, 89, 93], which may be a compensatory mechanism to limit damaging increased intra-renal pressure [93].

## Initiation of proinflammatory cytokines

### *Cytokines in the stenotic PUJ*

Transforming growth factor-beta (TGF- $\beta$ ) expression is noted in human stenotic PUJ compared to normal controls [94]. Furthermore, the smooth muscle regulators endothelin-1 (smooth muscle constrictor) and adrenomedullin (smooth muscle relaxant) have been shown to be increased and decreased, respectively, in stenotic PUJ disease [95].

Analysis of paediatric renal pelvis tissue proximal to the PUJO for cytokines that show altered renal expression in nephropathy demonstrates increased TGF- $\beta$  and reduced macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ). In contrast, epidermal growth factor (EGF), monocyte chemoattractant peptide 1, interferon- $\gamma$ -inducible protein 10 and RANTES (regulated on activation normal T-cell expressed and secreted) mRNA expression are unchanged,

suggesting that TGF- $\beta$  and MIP-1 $\alpha$  play important roles in the development of PUJO [88, 96].

### *Intra-renal cytokines*

Increased intra-renal angiotensin II activates nuclear factor kappa B and ROCK (rho-associated coiled-coil-forming protein kinase), leading to cytokine release and interstitial macrophage infiltration and activation. Intra-renal selectins, integrins, intercellular-adhesion molecule 1, vascular cell adhesion molecule 1, interleukin 1, monocyte chemoattractant peptide 1, colony stimulating factor 1 and osteopontin expression are all involved in macrophage stimulation [11, 48, 88, 97]. Therefore, it appears that renal signals initiate and maintain the injurious inflammatory response to PUJO. Accordingly, both selectin and  $\beta$ 2-integrin knockout mouse models show reduced macrophage infiltration into the obstructed kidney after UUO [43, 44].

## Inflammatory infiltrates

Activated macrophages infiltrate the renal interstitium, sustaining the inflammatory response by releasing cytokines, such as TGF- $\beta$ 1, tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), and platelet-derived growth factor [11, 88].

## Profibrotic processes

Tubulointerstitial fibrosis is the final common pathway for many chronic kidney disorders, including obstructive uropathy, and is instigated by altered cytokine expression (Table 4). Activated resident interstitial myofibroblasts [98], expressing  $\alpha$ -smooth muscle actin (boosts cell contractility) [99], aggregate, proliferate and produce extracellular matrix. Extracellular matrix consisting of collagens I, III and IV, fibronectin, laminin and proteoglycans accumulates due to increased synthesis and reduced degradation [74, 100, 101]. Myofibroblasts amplify fibrosis by producing cytokines, including TGF- $\beta$ 1 and TNF- $\alpha$  [11]. Parenchymal damage and renal dysfunction results, such that in children with PUJO the extent of fibrosis significantly correlates with differential renal function [102].

Angiotensin II upregulation is central to the pathogenesis of obstructive nephropathy (Fig. 6) [11, 41, 45, 64, 68, 83, 84, 91, 103–112]. Angiotensinogen murine knockout studies have demonstrated that angiotensin II expression is responsible for at least 50% of renal fibrosis in chronic neonatal UUO [104]. Acting predominantly via the AT1 receptor [45, 105, 113] it regulates cytokine production and stimulates reactive oxygen species (ROS) generation, which in turn propagates the proinflammatory, fibrogenic state [48, 104]. The generation of ROS also causes proximal tubular degeneration by apoptosis, autophagy and necrosis, with consequent destruction of



**Table 3** Table showing the major cytokines, growth factors, chemokines, enzymes and cytoskeletal proteins which demonstrate altered intra-renal regulation in obstructive nephropathy, the timing of these changes and their mode of action

Protein <sup>a</sup>	Action	Change/timing	Species	Reference
Angiotensin II	Vasoregulatory, proinflammatory, proapoptotic, profibrotic	Increased 28 days Increased 1 week and 5 weeks Increased after mechanical stretch	Neonatal rat CUUO Adult rat CUUO In vitro podocytes	[63] [64] [65]
$\alpha$ -SMA	Increases myofibroblast contractility/EMT marker	Increased 5 days Increased 4 days	Neonatal rat CUUO Adult mouse CUUO	[39] [66]
Caspases	Proapoptotic	Increased 14 days Increased 1 day	Neonatal rat CUUO Adult rat CUUO	[67] [68]
Clusterin	Cytoprotective via pro-survival autophagy	Increased 5 days	Neonatal rat CUUO	[39]
COX-2	Polyuria and natriuresis, anti-apoptotic, antifibrotic	Increased 24 h Increased 3 days (mRNA)	Adult rat CBUO Adult mouse CUUO	[69] [70]
CTGF	Profibrotic	Increased 2 days (mRNA)	Adult rat CUUO	[45]
EGF	Epithelial survival factor	Decreased 7 days (mRNA) (Undetectable expression in neonatal rat kidney before 4 days) Decreased 33 days Decreased at pyeloplasty (mean age 2 years) (mRNA) Decreased at pyeloplasty (mean age 5 years)	Neonatal rat CUUO Neonatal rat both CUUO and 5 day CUUO then release Human renal biopsy	[71] [39] [72] [73]
ET-1	Vasoconstrictor	Increased 2 days (mRNA)	Adult rat CUUO	[45]
Fas-L	Proapoptotic	Increased 1 day (mRNA)	Adult rat CUUO	[68]
HSP-70	Antiapoptotic	Decreased 14 days	Neonatal CUUO	[67]
ICAM-1	Proinflammatory	Increased 3 days	Adult mouse CUUO	[74]
Il-6	Proinflammatory	Increased 2 days (mRNA)	Adult rat CUUO	[45]
Integrin ( $\beta$ 1)	Profibrotic	Increased 3 days Increased after mechanical stretch	Adult mouse CUUO In vitro proximal tubular cells	[75] [76]
MCP-1	Proinflammatory	Increased 12 days, no change 4 days Increased 2 days (mRNA) Increased at pyeloplasty (mean age 2 years) (mRNA)	Neonatal rat CUUO Adult rat CUUO Human renal biopsy	[77] [45] [72]
MMP 2 and 9	ECM degradation	Decreased 3 days	Adult mouse CUUO	[74]
PAI-1	Profibrotic, inhibits ECM degradation	Increased 7 days	Adult mouse CUUO	[78]
PDGF	Profibrotic	Increased 4 days	Adult mouse CUUO	[66]
NF- $\kappa$ B	Regulatory transcription factor	Increased 2 days	Adult mouse CUUO	[45]
Nitric oxide	Vasodilator, anti-apoptotic, antifibrotic	Decreased 14 days	Neonatal rat CUUO	[67, 79]
Renin	Cleaves angiotensinogen, upregulates renin-angiotensin system	Increased 3 days (mRNA) Increased 5 days Increased 14 days (mRNA) Increased 4–5 weeks Increased 24 h Increased after mechanical stretch	Neonatal rat CUUO Neonatal rat CUUO Neonatal rat CUUO Neonatal rat CUUO Adult rat CUUO In vitro proximal tubular cells	[71] [39] [63] [80] [81] [82]
TGF- $\beta$	Proinflammatory, proapoptotic, profibrotic, stimulates EMT	Increased 1 day (mRNA) Increased 33 days Increased 3 days (mRNA) Increased at pyeloplasty (mean age 5 years)	Neonatal rat CUUO Neonatal rat both CUUO and 5 day CUUO then release Adult rat CUUO Human renal biopsy	[71] [39] [83] [73]
TIMP-1	Profibrotic, inhibits ECM degradation	Increased 5 days Increased 3 days	Adult rat CUUO Adult mouse CUUO	[84] [74]
TNF- $\alpha$	Proapoptotic, proinflammatory	Increased 14 days (mRNA) Increased 1 day Increased 2 days (mRNA) Increased 1 day	Neonatal rat CUUO Adult rat CUUO Adult rat CUUO Adult rat CUUO	[85] [68] [45] [68]
VCAM-1	Proinflammatory	Increased 3 days (mRNA)	Adult mouse CUUO	[86]

**Table 3** (continued)

Protein <sup>a</sup>	Action	Change/timing	Species	Reference
VEGF (podocytes)	Endothelial survival factor	Increased 28 days Decreased 14 days	Neonatal PUUO Neonatal CUUO	[87] [87]
VEGF (tubules)	Endothelial survival factor	Variable expression Decreased 14 days	Neonatal PUUO Neonatal CUUO	[87] [87]
Vimentin	Intermediate filament protein/ EMT marker	Increased 5 days	Neonatal rat CUUO	[39]
WT-1	Transcriptional regulator, key role in renal development	Decreased 14 days	Neonatal rat CUUO	[85]


Change is compared to sham animal or control human kidney and refers to protein expression unless otherwise stated. Timing is days after creation of unilateral ureteric obstruction (UUO)

CUUO, Complete UUO; CBUO complete bilateral ureteric obstruction; PUUO, partial UUO

<sup>a</sup>  $\alpha$ -SMA, Alpha-smooth muscle actin; COX-2, cyclooxygenase 2; CTGF, connective tissue growth factor; ECM, extracellular matrix; EGF, epidermal growth factor; EMT, epithelial–mesenchymal transition; FasL, Fas ligand; HSP-70, heat shock protein 70; ICAM-1, intercellular adhesion molecule 1; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein 1; MMP, matrix metalloproteinase; NF- $\kappa$ B, nuclear factor kappa-light-chain-enhancer of activated B cells; TGF- $\beta$ , transforming growth factor-beta; TIMP-1, tissue inhibitor of metalloproteinases 1; TNF- $\alpha$ , tumour necrosis factor-alpha; VCAM-1, vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor; WT-1, Wilms tumor protein

the glomerulotubular junction, resulting in the formation of atubular glomeruli [41, 109].

TGF- $\beta$ 1 is a profibrotic cytokine and fibroblast chemoattractant which plays a major role in fibrosis development via SMAD-dependent and -independent pathways (Fig. 7) [74–76, 114–118]. Renal TGF- $\beta$  expression is increased in experimental UUO [83, 103, 105, 107, 119–121] and children with PUJO, being positively correlated with the histopathologic grade, radioisotope drainage half time (t1/2) and post-void washout and negatively correlated with pre-operative differential renal function [73, 122].



**Fig. 5** Major mechanisms of renal injury in PUJO. *GFR* glomerular filtration rate, *TGF* transforming growth factor

Nitric oxide is an endogenous vasodilator that protects against tubulointerstitial fibrosis and proximal tubular oxidant injury in obstructive nephropathy [79, 84, 123]. Animal models [111, 124, 125] and human studies of PUJO show altered endothelial NO synthase (eNOS) and inducible NO synthase (iNOS) expression/activity together with reduced NO production. Lower eNOS expression/activity is associated with worse creatinine clearance, reduced differential renal function [90, 126] and increased fibrosis [90, 126], oxidant injury and apoptosis [67, 79].

### Antifibrotic processes


Renal cyclooxygenase 2 (COX-2) expression and prostaglandin production in experimental UUO is increased [69] and may be a protective response. COX-2 inhibition worsens obstructive nephropathy, while prostacyclin analogue

**Table 4** Cytokines, growth factors, enzymes and adhesion molecules promoting or preventing tubulointerstitial fibrosis in ureteric obstruction

Molecules PROMOTING tubulointerstitial fibrosis in ureteric obstruction	Molecules PREVENTING tubulointerstitial fibrosis in ureteric obstruction
Angiotensin II	EGF
CTGF	MMP
ICAM-1	Nitric oxide
Integrins	VEGF
PAI-1	
PDGF	
TGF- $\beta$	
TIMP-1	

PAI-1, Plasminogen activator inhibitor 1; PDGF, platelet-derived growth factor

**Fig. 6** Major pathways involved in the development of obstructive nephropathy derived from animal and human studies. *ET-1* Endothelin 1, *iNOS* inducible nitric oxide synthase, *PT* proximal tubule, *RAAS* renin–angiotensin–aldosterone system, *RANTES* regulated on activation normal T-cell expressed and secreted, *RBF* renal blood flow, *ROS* reactive oxygen species. For other abbreviations, see footnotes to Tables 3 and 4



(ONO-1301) supplementation alleviates UO-induced fibrosis [127].


## Cellular apoptosis

Apoptosis affects podocytes and endothelial and epithelial cells within the kidney, leading to loss of glomeruli, peritubular capillaries and tubules [11]. Tubular cell mechanical stretch is a potent stimulator of apoptosis [91, 128] that is mediated via TGF-β1 and TNF-α [68, 110] released from tubular cells and infiltrating macrophages [88]. Other proapoptotic factors increased after UO include Fas-L [45], p53, caspases and ceramide [11].

Downregulation of anti-apoptotic factors, including EGF, eNOS, NO, vascular endothelial growth factor, heat shock protein 70 and Wilms tumour-1, compounds the renal injury [11, 67, 88, 128, 129].

## Tubular function impairment

Ureteric obstruction leads to reduced renal expression of the V2 (vasopressin) receptor [130], renal sodium and urea transporters [131–133] and aquaporins [134–136]. Aquaporins are a family of transmembrane proteins normally expressed by mammalian kidney [137] and urothelium [138, 139] that mediate water movement across the cell membrane along an osmotic gradient [140]. Reduced renal aquaporin expression



**Fig. 7** Transforming growth factor  $\beta 1$  (*TGF- $\beta 1$* ) signalling via the SMAD-dependent pathway. Unilateral ureteric obstruction induces increased *TGF- $\beta 1$*  and *TGF- $\beta$  receptor II* (*TGF $\beta$ RII*) expression, upregulating SMAD 2 and 3 and downregulating SMAD 7 (inhibitory for SMAD 2 and 3).  $\beta 1$ -integrin is upregulated by both SMAD signalling and mechanical stretch and contributes to a positive feedback loop regulating *TGF- $\beta 1$*  expression via the c-SRC and STAT-3 pathways. *EMT* Epithelial mesenchymal transformation

in experimental UUO is noted within 24 h of complete obstruction [134]. Similarly, renal aquaporins are downregulated in children undergoing pyeloplasty, and in both human and animal models this reduction is associated with polyuria and reduced concentrating ability following relief of obstruction [141–143].

## Genetic mechanistic clues in PUJO

Phenotypes similar to PUJO have been noted in numerous transgenic mouse models. Many genes involved in ureteric smooth muscle proliferation and differentiation are implicated, supporting a primary myogenic aetiology. Importantly, one of these genes has been implicated in human disease (Table 2).

Mutations in *TBX18*, the gene coding for T Box protein 18, have been reported in association with congenital anomalies of the kidney and urinary tract (CAKUT). In particular, a heterozygous *TBX18* truncating mutation (c.1010delG) showing autosomal dominant inheritance has been described across four generations of a family with CAKUT, and predominantly PUJO [56]. The transcription factor TBX18 is necessary for normal smooth muscle cell proliferation, differentiation and localisation around the developing urothelial stalk [24]. TBX18 also directs epithelial proliferation and when absent leads to an abnormally short ureteric bud [28].

In the majority of patients, however, PUJO is a polygenic disorder without an obviously inherited genetic component [11].

## Potential therapeutic molecular targets in PUJO

Human and animal studies have highlighted a number of potential therapeutic targets that could be manipulated to alleviate the nephropathy sustained secondary to PUJO. Several drugs targeting these pathways have been assessed in rodent UUO models as described below, however, to our knowledge none of these therapies have been trialed in childhood human PUJO.

### Angiotensin-converting enzyme and AT1 receptor inhibitors

In adult rodent UUO models angiotensin-converting enzyme (ACE) inhibitors and AT1 receptor inhibitors given prophylactically (for the duration of obstruction) are beneficial in alleviating nephropathy. Specifically, they reduce *TGF- $\beta$*  [121, 144] and *TNF- $\alpha$*  [106] expression, as well as macrophage infiltration and tubulointerstitial fibrosis [84, 105, 145]. Additionally, AT1 receptor inhibitors improve tubular function by improving RBF and GFR and attenuating the reduction in sodium transporter and aquaporin 2 (AQP2) expression, thus reducing polyuria and natriuresis [92, 112].

ACE inhibitors reduce both AT1 and AT2 receptor stimulation [146] and indirectly increase NO levels via bradykinin generation [84]. This may explain why they confer additional benefits, particularly anti-inflammatory, compared to AT1 receptor inhibitors [97]. Unfortunately, inhibition of angiotensin during either the period of nephrogenesis (first 10 days after UUO) or renal maturation (second 10 days after UUO) in neonatal partial UUO exacerbates renal injury in both the obstructed and contralateral kidney [147, 148]. Such studies highlight the importance of these pathways in normal kidney development and maturation.

However, it is important to remember that ACE inhibitors and AT1 receptor inhibitors are frequently used in children with chronic kidney disease, in whom they significantly reduce proteinuria [149] despite not significantly alleviating the natural decline in excretory function [150, 151]. They are largely well tolerated, with no apparent effect on growth and development and a low incidence of side effects such as hyperkalaemia, hypotension and renal injury [149].

### Hydroxymethylglutaryl-CoA reductase inhibitors (statins)

Statins ameliorate nephropathy when administered prophylactically in adult and neonatal rodent UUO models by reducing

renal cytokine production (TGF- $\beta$ , TNF- $\alpha$ ), macrophage infiltration, oxidative stress, apoptosis and tubulointerstitial fibrosis [85, 152, 153]. These pleiotropic effects are achieved through decreased Ras/ERK/Akt signalling [154] and increased NO bioavailability [155]. Importantly, statins remain beneficial in neonatal rodent UUO where an improvement in tubular dilatation and glomerular number and size are also seen [67, 79, 85]. Functionally, in UUO models, statins improve GFR and microalbuminuria [156] and increase urinary concentrating ability via boosting AQP2 expression [157].

Statins are commonly used and usually well tolerated in adults. Side effects of treatment include hepatic dysfunction, diabetes mellitus, benign proteinuria, peripheral neuropathy, myalgia and rhabdomyolysis [158]. A 10-year follow-up study of children ( $\geq 8$  years) treated with statins for familial hypercholesterolaemia demonstrated that few discontinue therapy due to side effects and that there were no serious adverse reactions [159]. In that same study, growth, puberty and educational parameters were also unaffected compared to controls [159].

### TGF- $\beta$ modulation

Prophylactic TGF- $\beta$  receptor inhibition is renoprotective in adult rodent UUO models, reducing apoptosis, macrophage infiltration, fibrosis, proximal tubular atrophy and atubular glomeruli formation [117, 160]. Similarly, anti-TGF- $\beta$  antibody treatment increases NOS expression while reducing apoptosis and fibrosis [110]. Conversely, prophylactic TGF- $\beta$  receptor inhibition in neonatal mouse UUO causes widespread renal necrosis, exacerbating the injury in the obstructed kidney and highlighting the differing responses to signalling cascades during renal development [117].

Anti-TGF- $\beta$  antibody treatment (GC1008) has been trialled in human oncological disease and was generally well tolerated. However, side effects included gingivitis, fatigue and skin rashes, including keratoacanthoma and squamous cell carcinoma development (melanoma patients only). GC1008 treatment has not progressed beyond phase II clinical trials as drug development was discontinued by the manufacturer [161].

### COX-2 inhibition

In adult rodent bilateral ureteric obstruction COX-2 inhibition alleviates AQP2 and sodium transporter downregulation and improves post-obstructive polyuria, which would appear to be beneficial [69]. Conversely, other studies have demonstrated that both genetic COX-2 knockout and prophylactic COX-2 inhibition in adult rodent UUO models increase tubular injury, apoptosis and fibrosis, thereby negating potential use in the clinical setting [70, 162].

Chronic celecoxib (COX-2 inhibitor) use in children demonstrates a similar frequency of adverse events to non-selective non-steroidal anti-inflammatory drugs, which are most frequently gastrointestinal side effects [163].

### Other potential therapeutic options

Other potential therapeutic pathways include those that are able to increase the vasoactive molecule NO, as this has been shown to reduce tubulointerstitial fibrosis in adult rodent UUO models [84]. Although both ACE inhibitors and statins increase NO bioavailability, this is an indirect effect at the expense of drug-related side effects.

Dietary nitrate supplementation is a novel therapeutic option which directly targets the NO pathway, increasing NO generation via nitrite production. Nitrite also has cytoprotective effects independent of NO by influencing mitochondrial function [164], and when administered during rodent ischaemia reperfusion studies reduces renal injury [165].

Despite former concerns associating nitrates with methaemoglobinaemia and carcinogenesis, the nitrate–nitrite–NO pathway is increasingly implicated in a protective role in humans [166]. Further investigation of dietary nitrate supplementation as a potential therapy in obstructive nephropathy is warranted.

### Urinary biomarkers

Identifying early urinary biomarkers in PUJO may be beneficial for the diagnosis, management and prognosis of this condition. Such biomarkers would enable timely detection of children with ‘damaging’ hydronephrosis who require surgery to protect renal function, while avoiding surgery in those with ‘safe’ hydronephrosis.

### Urinary biomarkers in animal studies

There is little data on urinary biomarkers from animal studies. Proteomics using a rat UUO model demonstrated increased urinary and renal levels of alpha-actinin-1 and moesin at 1 week which corresponded with histological evidence of tubular injury. Following 3 weeks of UUO urine and renal levels of vimentin, annexin A1 and clusterin were significantly elevated, corresponding with substantial renal interstitial fibrosis [167].

### Urinary biomarkers in human studies

Many urinary cytokines, growth factors, chemokines, tubular enzymes and tubular transport proteins have been investigated



**Table 5** Urinary proteins from studies in children with pelvi-ureteric junction obstruction

Urinary protein (corrected for creatinine) <sup>a</sup>	Primary measured group	Comparators	Bladder urine protein level	Sensitivity/specificity/accuracy <sup>b</sup>	Post-operative bladder urine (compared to pre-operative)	Ref
ALP	Pyeloplasty	CMP	Increased pre-operative	Se 91.4%/ Sp 100%/ Ac 94%	Decreased 12 months post-operative	[168]
Angiotensinogen	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 93.3%/ Sp 60% <sup>c</sup>		[169]
B2-microglobulin	PUJO*	Healthy control	Increased		Decreased 42 months post-operative	[170]
B2-microglobulin	Pyeloplasty	Healthy control	No change			[171]
Ca19-9	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 76% <sup>d</sup> /Sp 85% <sup>d</sup>	Decreased 3 months post-operative	[172]
Ca19-9	Pyeloplasty	Healthy control Hydrocoele/renal cyst	Increased pre-operative	Se 100% <sup>e</sup> / Sp 82.6% <sup>e</sup>	Decreased 3 months post-operative	[173]
CyC	Pyeloplasty	Healthy control	No change			[171]
EGF	PUJO*	Healthy control	Decreased (obstructed group only)		No change	[170]
EGF	Pyeloplasty	Healthy control	Decreased pre-operative		Increased	[174]
EGF	Pyeloplasty	Healthy control	Increased pre-operative	Se 70.4%/Sp 69.2%	Decreased 3 months and 1 year post-operative	[175]
EGF	Pyeloplasty	Healthy control	No change			[176]
ET-1	Pyeloplasty	Healthy control VUR	Increased pre-operative	Se 74.3%/Sp 90%/ Ac 81.5%	Decreased 12 months post-operative	[177]
γGT	Pyeloplasty	CMP	Increased pre-operative	Se 62.9%/Sp 100%/Ac 74%	Decreased 12 months post-operative	[168]
HO-1	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 72.2% <sup>e</sup> /Sp 78.1% <sup>e</sup>	Decreased 1 month post-operative	[178]
IP-10	Pyeloplasty	Healthy control	No change			[175]
KIM-1	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 100% <sup>c</sup> /Sp 71.4% <sup>e</sup>		[179]
MCP-1	Pyeloplasty	Healthy control	Increased pre-operative	Se 77.8%/Sp 69.2%	Decreased 3 months and 1 year post-operative	[175]
MCP-1	PUJO*	Healthy control	Increased		Decreased 42 months post-operative	[170]
MCP-1	Pyeloplasty	Healthy control	Increased pre-operative			[174]
MCP-1	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 100% <sup>c</sup> /Sp 0% <sup>c</sup>	Remains high 3 months post-operative	[180]
MIP-1α	Pyeloplasty	Healthy control	Decreased pre-operative		Increased 1 year post-operative	[175]
NAG	Pyeloplasty	CMP	Increased pre-operative	Se 97.1%/Sp 80%/Ac 92%	Decreased 12 months post-operative	[168]
NGAL	Pyeloplasty	Healthy control	No change			[171]
NGAL	Pyeloplasty	Healthy control	Increased pre-operative			[181]
NGAL	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 100% <sup>c</sup> /Sp 28.6% <sup>e</sup>	Decreased 3 months post-operative	[179]
OPN	Pyeloplasty	Healthy control	No change			[171]
OPN	Pyeloplasty	Healthy control CMP	Increased pre-operative	Se 98.5% <sup>c</sup> /Sp 10.5% <sup>e</sup>	Remains high 3 months post-operative	[180]
RANTES	Pyeloplasty	Healthy control	No change			[175]
TGF-β	Pyeloplasty	Healthy control	Increased pre-operative	Se 100%/Sp 80%/Ac 90.8%	Decreased 1 year post-operative	[176]
TGF-β	Pyeloplasty	CMP	Increased pre-operative	Se 82%/Sp 86%		[182]

Generally, the primary group measured is children undergoing pyeloplasty; these children are then compared to healthy controls and/or conservatively managed children with PUJO (CMP). The exception in the studies listed in the table is labelled PUJO\*, which includes children with conservatively managed PUJO split into 'functional' (t1/2 of renogram < 0 min) and 'obstructed' (t1/2 of renogram > 20 min). In these studies voided urine from children undergoing pyeloplasty was only obtained 42 months post-operative

<sup>a</sup> ALP, Alkaline phosphatase; Ca19-9, carbohydrate antigen 19-9; CyC, cystatin-C; HO-1, heme oxygenase-1; γGT, gamma-glutamyl transferase; IP-10, interferon-γ-inducible protein 10; KIM-1, kidney injury molecule-1; MIP-1α, macrophage inflammatory protein-1α; NAG, N-acetyl-beta-D-glucosaminidase; NGAL, neutrophil gelatinase-associated lipocalin; OPN, osteopontin; RANTES, regulated on activation normal T-cell expressed and secreted

<sup>b</sup> Where applicable sensitivity (Se), specificity (Sp) and accuracy (Ac) of the test at best threshold value from receiver operating characteristic curve analysis is presented

<sup>c</sup> To detect differential renal function (DRF) of <40% out of all hydronephrosis cases

<sup>d</sup> To detect pyeloplasty cases out of all hydronephrosis cases

<sup>e</sup> To detect pyeloplasty cases out of all cases



in children undergoing pyeloplasty for PUJO. Studies with conservatively managed PUJO as a comparator are most useful to identify biomarkers able to aid selection of patients for surgery. Potential urinary biomarker proteins measured in bladder urine samples are presented in Table 5.

Finding a suitable biomarker test with high sensitivity, specificity and predictive value is challenging [88], not least because these markers are excreted in health as well as disease, show significant intra- and inter-patient variation and may be affected by patient age, the presence of urinary tract infection and other renal disorders [174, 183].

A recent systematic review of urinary and serum biomarkers included 14 studies which reported data on 380 surgically managed PUJO patients, 174 conservatively managed patients and 213 controls [184]. This review reported a wide-range of sometimes conflicting results, and the authors were unable to draw any firm conclusions, attributing this to differences in study design with heterogeneous age groups, various or absent control groups and often short durations of follow-up [184].

More successfully, proteomics of neonatal urine has identified a panel of 51 peptides which distinguish obstruction severity. When implemented in a prospective blinded study it had an accuracy of 94% to predict future need for surgery in newborns with PUJO [185]. However, beyond 1 year of age the sensitivity and specificity of this proteome profile diminished significantly [186].

A single biomarker able to guide selection of patients for pyeloplasty has not yet been identified, indicating a panel of biomarkers may be necessary to achieve this.

## Conclusions

Managing children with asymptomatic intrinsic PUJO is a significant challenge for clinicians. Animal and human studies have expanded our understanding of the molecular mechanisms involved in the aetiology of obstruction and in particular the progression of the renal insult. Upregulation of the RAAS and TGF- $\beta$  expression are fundamental to renal injury, which is attenuated in animal models by therapeutic inhibition of these pathways. Much, however, remains to be learned in order to identify molecular markers and targets useful in the day-to-day diagnosis and management of this condition.

## Future perspectives and unanswered questions in PUJO

- What is the underlying aetiology of intrinsic congenital PUJO? Does this explain the variable outcome of PUJO and can this be targeted therapeutically?

- Does individual ability to relieve intra-renal pressure determine disease progression?
- Are therapies tested in animals applicable in children to limit renal injury?
- Can urinary biomarkers improve early identification and thus outcome of children requiring pyeloplasty?

## Compliance with ethical standards

**Funding** Laura Jackson is funded by a joint Royal College of Surgeons of England/British Association of Paediatric Surgeons Fellowship (Awarded 2014). Richard Coward is funded by the Medical Research Council as a Senior Clinical Fellow MR/K010492/1.

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

1. Dudley JA, Haworth JM, McGraw ME, Frank JD, Tizard EJ (1997) Clinical relevance and implications of antenatal hydronephrosis. *Arch Dis Child Fetal Neonatal Ed* 76:F31–34
2. Brussels Free University Perinatal Nephrology Study Group, Ismaili K, Avni FE, Wissing KM, Hall M (2004) Long-term clinical outcome of infants with mild and moderate fetal pyelectasis: validation of neonatal ultrasound as a screening tool to detect significant nephrouropathies. *J Pediatr* 144:759–765
3. Jaswon MS, Dibble L, Puri S, Davis J, Young J, Dave R, Morgan H (1999) Prospective study of outcome in antenatally diagnosed renal pelvis dilatation. *Arch Dis Child Fetal Neonatal Ed* 80: F135–138
4. Woodward M, Frank D (2002) Postnatal management of antenatal hydronephrosis. *BJU Int* 89:149–156
5. Morris RK, Kilby MD (2008) Congenital urinary tract obstruction. *Best Pract Res Clin Obstet Gynaecol* 22:97–122
6. Corbett HJ, McCarthy L (2013) Hydronephrosis in children: pelviureteric junction dysfunction. *Surgery (Oxford)* 31:135–139
7. Hashim H, Woodhouse CRJ (2012) Ureteropelvic junction obstruction. *Eur Urol Suppl* 11:25–32
8. Ulman I, Jayanthi VR, Koff SA (2000) The long-term followup of newborns with severe unilateral hydronephrosis initially treated nonoperatively. *J Urol* 164:1101–1105
9. Hafez AT, McLorie G, Bagli D, Khoury A (2002) Analysis of trends on serial ultrasound for high grade neonatal hydronephrosis. *J Urol* 168(4 Pt 1):1518–1521
10. Chertin B, Pollack A, Koulikov D, Rabinowitz R, Hain D, Hadas-Halpren I, Farkas A (2006) Conservative treatment of ureteropelvic junction obstruction in children with antenatal diagnosis of hydronephrosis: lessons learned after 16 years of follow-up. *Eur Urol* 49:734–738
11. Chevalier RL, Thornhill BA, Forbes MS, Kiley SC (2010) Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy. *Pediatr Nephrol* 25:687–697

12. Gordon I, Dhillon HK, Gatanash H, Peters AM (1991) Antenatal diagnosis of pelvic hydronephrosis: assessment of renal function and drainage as a guide to management. *J Nucl Med* 32:1649–1654
13. Ransley PG, Dhillon HK, Gordon I, Duffy PG, Dillon MJ, Barratt TM (1990) The postnatal management of hydronephrosis diagnosed by prenatal ultrasound. *The J Urol* 144(2 Pt 2):584–587, discussion 593–584
14. Csaicsich D, Greenbaum LA, Aufricht C (2004) Upper urinary tract: when is obstruction obstruction? *Curr Opin Urol* 14:213–217
15. Stringer MD, Yassaie S (2013) Is the pelviureteric junction an anatomical entity? *J Pediatr Urol* 9:123–128
16. Shafik A, Al-Sherif A (1999) Ureteropelvic junction: a study of its anatomical structure and function. *Ureteropelvic junction sphincter? Eur Urol* 36:150–156, discussion 156–157
17. Santicoli P, Maggi CA (1998) Myogenic and neurogenic factors in the control of pyeloureteral motility and ureteral peristalsis. *Pharmacol Rev* 50:683–722
18. Nemeth L, O'Briain DS, Puri P (2001) Demonstration of neuronal networks in the human upper urinary tract using confocal laser scanning microscopy. *J Urol* 166:255–258
19. Takasato M, Little MH (2015) The origin of the mammalian kidney: implications for recreating the kidney in vitro. *Development* 142:1937–1947
20. Nagalakshmi VK, Yu J (2015) The ureteric bud epithelium: morphogenesis and roles in metanephric kidney patterning. *Mol Reprod Dev* 82:151–166
21. Yu J, Carroll TJ, McMahon AP (2002) Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. *Development* 129:5301–5312
22. Brenner-Anantharam A, Cebrian C, Guillaume R, Hurtado R, Sun TT, Herzlinger D (2007) Tailbud-derived mesenchyme promotes urinary tract segmentation via BMP4 signaling. *Development* 134:1967–1975
23. Caubit X, Lye CM, Martin E, Core N, Long DA, Vola C, Jenkins D, Garratt AN, Skaer H, Woolf AS, Fasano L (2008) Teashirt 3 is necessary for ureteral smooth muscle differentiation downstream of SHH and BMP4. *Development* 135:3301–3310
24. Airik R, Bussen M, Singh MK, Petry M, Kispert A (2006) Tbx18 regulates the development of the ureteral mesenchyme. *J Clin Invest* 116:663–674
25. Mahoney ZX, Sammut B, Xavier RJ, Cunningham J, Go G, Brim KL, Stappenbeck TS, Miner JH, Swat W (2006) Discs-large homolog 1 regulates smooth muscle orientation in the mouse ureter. *Proc Natl Acad Sci USA* 103:19872–19877
26. Crelin ES (1978) Normal and abnormal development of ureter. *Urology* 12:2–7
27. Alcaraz A, Vinaixa F, Tejedo-Mateu A, Fores MM, Gotzens V, Mestres CA, Oliveira J, Carretero P (1991) Obstruction and recanalization of the ureter during embryonic development. *J Urol* 145:410–416
28. Woolf AS, Davies JA (2013) Cell biology of ureter development. *J Am Soc Nephrol* 24:19–25
29. Matsuno T, Tokunaka S, Koyanagi T (1984) Muscular development in the urinary tract. *J Urol* 132:148–152
30. Chang CP, McDill BW, Neilson JR, Joist HE, Epstein JA, Crabtree GR, Chen F (2004) Calcineurin is required in urinary tract mesenchyme for the development of the pyeloureteral peristaltic machinery. *J Clin Invest* 113:1051–1058
31. Miyazaki Y, Tsuchida S, Nishimura H, Pope JC 4th, Harris RC, McKanna JM, Inagami T, Hogan BL, Fogo A, Ichikawa I (1998) Angiotensin induces the urinary peristaltic machinery during the perinatal period. *J Clin Invest* 102:1489–1497
32. Zhang PL, Peters CA, Rosen S (2000) Ureteropelvic junction obstruction: morphological and clinical studies. *Pediatr Nephrol* 14:820–826
33. Murakumo M, Nonomura K, Yamashita T, Ushiki T, Abe K, Koyanagi T (1997) Structural changes of collagen components and diminution of nerves in congenital ureteropelvic junction obstruction. *J Urol* 157:1963–1968
34. Demirebilek S, Edali MN, Gurunluoglu K, Turkmen E, Tas E, Karaman A, Akin M, Aksoy RT, Celbis O, Uzun I (2006) Glial cell line-derived neurotrophic factor and synaptophysin expression in pelviureteral junction obstruction. *Urology* 67:400–405
35. Ozel SK, Emir H, Dervisoglu S, Akpolat N, Senel B, Kazez A, Soyler Y, Cetin G, Danismend N, Buyukunal SN (2010) The roles of extracellular matrix proteins, apoptosis and c-kit positive cells in the pathogenesis of ureteropelvic junction obstruction. *J Pediatr Urol* 6:125–129
36. Kaneto H, Orikasa S, Chiba T, Takahashi T (1991) Three-D muscular arrangement at the ureteropelvic junction and its changes in congenital hydronephrosis: a stereo-morphometric study. *J Urol* 146:909–914
37. Hosgor M, Karaca I, Ulukus C, Ozer E, Ozkara E, Sam B, Ucan B, Kurtulus S, Karkiner A, Temir G (2005) Structural changes of smooth muscle in congenital ureteropelvic junction obstruction. *J Pediatr Surg* 40:1632–1636
38. Aoki Y, Mori S, Kitajima K, Yokoyama O, Kanamaru H, Okada K, Yokota Y (2004) Id2 haploinsufficiency in mice leads to congenital hydronephrosis resembling that in humans. *Genes Cells* 9:1287–1296
39. Chevalier RL, Kim A, Thornhill BA, Wolstenholme JT (1999) Recovery following relief of unilateral ureteral obstruction in the neonatal rat. *Kidney Int* 55:793–807
40. Chevalier RL, Thornhill BA, Wolstenholme JT (1999) Renal cellular response to ureteral obstruction: role of maturation and angiotensin II. *Am J Physiol* 277(1 Pt 2):F41–47
41. Forbes MS, Thornhill BA, Chevalier RL (2011) Proximal tubular injury and rapid formation of atubular glomeruli in mice with unilateral ureteral obstruction: a new look at an old model. *Am J Physiol Ren Physiol* 301:F110–117
42. Forbes MS, Thornhill BA, Galarreta CI, Minor JJ, Gordon KA, Chevalier RL (2013) Chronic unilateral ureteral obstruction in the neonatal mouse delays maturation of both kidneys and leads to late formation of atubular glomeruli. *Am J Physiol Ren Physiol* 305:F1736–1746
43. Lange-Sperandio B, Cachat F, Thornhill BA, Chevalier RL (2002) Selectins mediate macrophage infiltration in obstructive nephropathy in newborn mice. *Kidney Int* 61:516–524
44. Lange-Sperandio B, Schimpfen K, Rodenbeck B, Chavakis T, Bierhaus A, Nawroth P, Thornhill B, Schaefer F, Chevalier RL (2006) Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. *Kidney Int* 69:81–88
45. Esteban V, Lorenzo O, Ruperez M, Suzuki Y, Mezzano S, Blanco J, Kretzler M, Sugaya T, Egido J, Ruiz-Ortega M (2004) Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. *J Am Soc Nephrol* 15:1514–1529
46. Thornhill BA, Burt LE, Chen C, Forbes MS, Chevalier RL (2005) Variable chronic partial ureteral obstruction in the neonatal rat: a new model of ureteropelvic junction obstruction. *Kidney Int* 67:42–52
47. Thornhill BA, Forbes MS, Marcinko ES, Chevalier RL (2007) Glomerulotubular disconnection in neonatal mice after relief of partial ureteral obstruction. *Kidney Int* 72:1103–1112
48. Klein J, Gonzalez J, Miravete M, Caubet C, Chaaya R, Decramer S, Bandin F, Bascands JL, Buffin-Meyer B, Schanstra JP (2011) Congenital ureteropelvic junction obstruction: human disease and animal models. *Int J Exp Pathol* 92:168–192

49. Wang Y, Puri P, Hassan J, Miyakita H, Reen DJ (1995) Abnormal innervation and altered nerve growth factor messenger ribonucleic acid expression in ureteropelvic junction obstruction. *J Urol* 154:679–683
50. Cutroneo G, Arena S, Anastasi G, Cervellione RM, Grimaldi S, Di Mauro D, Speciale F, Arena F, Di Benedetto V, Favalaro A, Magno C (2011) Altered cytoskeletal structure of smooth muscle cells in ureteropelvic junction obstruction. *J Urol* 185:2314–2319
51. Esther CR Jr, Howard TE, Marino EM, Goddard JM, Capecci MR, Bernstein KE (1996) Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. *Lab Invest* 74:953–965
52. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashii Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K (2000) ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. *J Clin Invest* 105:1345–1352
53. Nagata M, Tanimoto K, Fukamizu A, Kon Y, Sugiyama F, Yagami K, Murakami K, Watanabe T (1996) Nephrogenesis and renovascular development in angiotensinogen-deficient mice. *Lab Invest* 75:745–753
54. McDill BW, Li SZ, Kovach PA, Ding L, Chen F (2006) Congenital progressive hydronephrosis (cph) is caused by an S256L mutation in aquaporin-2 that affects its phosphorylation and apical membrane accumulation. *Proc Natl Acad Sci USA* 103:6952–6957
55. Lu W, Quintero-Rivera F, Fan Y, Alkuraya FS, Donovan DJ, Xi Q, Turbe-Doan A, Li QG, Campbell CG, Shanske AL, Sherr EH, Ahmad A, Peters R, Rilliet B, Parvex P, Bassuk AG, Harris DJ, Ferguson H, Kelly C, Walsh CA, Gronostajski RM, Devriendt K, Higgins A, Ligon AH, Quade BJ, Morton CC, Gusella JF, Maas RL (2007) NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects. *PLoS Genet* 3:e80
56. Vivante A, Kleppa MJ, Schulz J, Kohl S, Sharma A, Chen J, Shril S, Hwang DY, Weiss AC, Kaminski MM, Shukrun R, Kemper MJ, Lehnhardt A, Beetz R, Sanna-Cherchi S, Verbitsky M, Gharavi AG, Stuart HM, Feather SA, Goodship JA, Goodship TH, Woolf AS, Westra SJ, Doody DP, Bauer SB, Lee RS, Adam RM, Lu W, Reutter HM, Kehinde EO, Mancini EJ, Lifton RP, Tasic V, Lienkamp SS, Juppner H, Kispert A, Hildebrandt F (2015) Mutations in TBX18 cause dominant urinary tract malformations via transcriptional dysregulation of ureter development. *Am J Hum Genet* 97:291–301
57. Jenkins D, Caubit X, Dimovski A, Matevska N, Lye CM, Cabuk F, Gucev Z, Tasic V, Fasano L, Woolf AS (2010) Analysis of TSHZ2 and TSHZ3 genes in congenital pelvi-ureteric junction obstruction. *Nephrol Dial Transplant* 25:54–60
58. Lye CM, Fasano L, Woolf AS (2010) Ureter myogenesis: putting Teashirt into context. *J Am Soc Nephrol* 21:24–30
59. Pope JC 4th, Showalter PR, Milam DF, Brock JW (1994) Intrapelvic pressure monitoring in the partially obstructed porcine kidney. *Urology* 44:565–571
60. Holden D, George NJ, Rickards D, Barnard RJ, O'Reilly PH (1984) Renal pelvic pressures in human chronic obstructive uropathy. *Br J Urol* 56:565–570
61. Kinn AC (1981) Pressure flow studies in hydronephrosis. *Scand J Urol Nephrol* 15:249–255
62. Chevalier RL (1984) Chronic partial ureteral obstruction in the neonatal guinea-pig. 2. Pressure-gradients affecting glomerular-filtration rate. *Pediatr Res* 18:1271–1277
63. Yoo KH, Norwood VF, el-Dahr SS, Yosipiv I, Chevalier RL (1997) Regulation of angiotensin II AT1 and AT2 receptors in neonatal ureteral obstruction. *Am J Physiol* 273:R503–509
64. el-Dahr SS, Gee J, Dipp S, Hanss BG, Vari RC, Chao J (1993) Upregulation of renin–angiotensin system and downregulation of kallikrein in obstructive nephropathy. *Am J Physiol* 264:F874–881
65. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ (2004) Activation of a local tissue angiotensin system in podocytes by mechanical strain. *Kidney Int* 65:30–39
66. Taneda S, Hudkins KL, Topouzis S, Gilbertson DG, Ophascharoensuk V, Truong L, Johnson RJ, Alpers CE (2003) Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. *J Am Soc Nephrol* 14:2544–2555
67. Manucha W, Kurban F, Mazzei L, Benardon ME, Bocanegra V, Tosi MR, Valles P (2011) eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy. *Eur J Pharmacol* 650:487–495
68. Misseri R, Meldrum DR, Dinarello CA, Dagher P, Hile KL, Rink RC, Meldrum KK (2005) TNF- $\alpha$  mediates obstruction-induced renal tubular cell apoptosis and proapoptotic signaling. *Am J Physiol Ren Physiol* 288:F406–411
69. Norregaard R, Jensen BL, Li C, Wang W, Knepper MA, Nielsen S, Frokiaer J (2005) COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. *Am J Physiol Ren Physiol* 289:F322–333
70. Nilsson L, Madsen K, Krag S, Frokiaer J, Jensen BL, Norregaard R (2015) Disruption of cyclooxygenase type 2 exacerbates apoptosis and renal damage during obstructive nephropathy. *Am J Physiol Ren Physiol* 309:F1035–1048
71. Chung KH, Chevalier RL (1996) Arrested development of the neonatal kidney following chronic ureteral obstruction. *J Urol* 155:1139–1144
72. Bartoli F, Gesualdo L, Paradies G, Caldarulo E, Infante B, Grandaliano G, Monno R, Leggio S, Salzillo F, Schena FP, Leggio A (2000) Renal expression of monocyte chemotactic protein-1 and epidermal growth factor in children with obstructive hydronephrosis. *J Pediatr Surg* 35:569–572
73. Yang Y, Hou Y, Wang CL, Ji SJ (2006) Renal expression of epidermal growth factor and transforming growth factor- $\beta$ 1 in children with congenital hydronephrosis. *Urology* 67:817–821, discussion 821–812
74. Cai G, Zhang X, Hong Q, Shao F, Shang X, Fu B, Feng Z, Lin H, Wang J, Shi S, Yin Z, Chen X (2008) Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. *Nephrol Dial Transplant* 23:1861–1875
75. Yeh YC, Wei WC, Wang YK, Lin SC, Sung JM, Tang MJ (2010) Transforming growth factor- $\beta$ 1 induces Smad3-dependent  $\beta$ 1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. *Am J Pathol* 177:1743–1754
76. Hamzeh MT, Sridhara R, Alexander LD (2015) Cyclic stretch-induced TGF- $\beta$ 1 and fibronectin expression is mediated by  $\beta$ 1-integrin through c-Src- and STAT3-dependent pathways in renal epithelial cells. *Am J Physiol Ren Physiol* 308:F425–436
77. Silverstein DM, Travis BR, Thornhill BA, Schurr JS, Kolls JK, Leung JC, Chevalier RL (2003) Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. *Kidney Int* 64:25–35
78. Samarakoon R, Overstreet JM, Higgins SP, Higgins PJ (2012) TGF- $\beta$ 1-SMAD/p53/USF2-PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. *Cell Tissue Res* 347:117–128
79. Garcia IM, Mazzei L, Benardon ME, Oliveros L, Cuello-Carrion FD, Gil Lorenzo A, Manucha W, Valles PG (2012) Caveolin-1-eNOS/Hsp70 interactions mediate rosuvastatin antifibrotic effects in neonatal obstructive nephropathy. *Nitric Oxide* 27:95–105



80. el-Dahr SS, Gomez RA, Gray MS, Peach MJ, Carey RM, Chevalier RL (1990) In situ localization of renin and its mRNA in neonatal ureteral obstruction. *Am J Physiol* 258:F854–862
81. Pimentel JL Jr, Martinez-Maldonado M, Wilcox JN, Wang S, Luo C (1993) Regulation of renin–angiotensin system in unilateral ureteral obstruction. *Kidney Int* 44:390–400
82. Ricardo SD, Franzoni DF, Roesener CD, Crisman JM, Diamond JR (2000) Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells. *Am J Physiol Ren Physiol* 278:F708–716
83. Kaneto H, Morrissey J, Klahr S (1993) Increased expression of TGF- $\beta$  1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. *Kidney Int* 44:313–321
84. Morrissey JJ, Ishidoya S, McCracken R, Klahr S (1996) Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. *J Am Soc Nephrol* 7:2202–2212
85. Mazzei LJ, Garcia IM, Altamirano L, Docherty NG, Manucha W (2012) Rosuvastatin preserves renal structure following unilateral ureteric obstruction in the neonatal rat. *Am J Nephrol* 35:103–113
86. Han H, Zhu J, Wang Y, Zhu Z, Chen Y, Lu L, Jin W, Yan X, Zhang R (2017) Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction. *J Pathol* 241:80–90
87. Burt LE, Forbes MS, Thornhill BA, Kiley SC, Chevalier RL (2007) Renal vascular endothelial growth factor in neonatal obstructive nephropathy. I. Endogenous VEGF. *Am J Physiol Ren Physiol* 292:F158–167
88. Madsen MG (2013) Urinary biomarkers in hydronephrosis. *Dan Med J* 60:B4582
89. Moody TE, Vaughn ED Jr, Gillenwater JY (1975) Relationship between renal blood flow and ureteral pressure during 18 hours of total unilateral urethral occlusion. Implications for changing sites of increased renal resistance. *Invest Urol* 13:246–251
90. Valles PG, Pascual L, Manucha W, Carrizo L, Ruttler M (2003) Role of endogenous nitric oxide in unilateral ureteropelvic junction obstruction in children. *Kidney Int* 63:1104–1115
91. Cachat F, Lange-Sperandio B, Chang AY, Kiley SC, Thornhill BA, Forbes MS, Chevalier RL (2003) Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. *Kidney Int* 63:564–575
92. Topcu SO, Pedersen M, Norregaard R, Wang G, Knepper M, Djurhuus JC, Nielsen S, Jorgensen TM, Frokiaer J (2007) Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. *Am J Physiol Ren Physiol* 292:F736–748
93. Koff SA (1985) Pressure volume relationships in human hydronephrosis. *Urology* 25:256–258
94. Yang Y, Zhou X, Gao H, Ji SJ, Wang C (2003) The expression of epidermal growth factor and transforming growth factor- $\beta$  1 in the stenotic tissue of congenital pelvi-ureteric junction obstruction in children. *J Pediatr Surg* 38:1656–1660
95. Knerr I, Nyul Z, Miller J, Rosch W, Dotsch J, Repp R, Weidner W, Rascher W (2001) Increased endothelin-1 and decreased adrenomedullin gene expression in the stenotic tissue of congenital pelvi-ureteric junction obstruction in children. *BJU Int* 87: 667–671
96. Seremetis GM, Maizels M (1996) TGF- $\beta$  mRNA expression in the renal pelvis after experimental and clinical ureteropelvic junction obstruction. *J Urol* 156:261–266
97. Klahr S, Ishidoya S, Morrissey J (1995) Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. *Am J Kidney Dis* 26:141–146
98. Picard N, Baum O, Vogetseder A, Kaissling B, Le Hir M (2008) Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. *Histochem Cell Biol* 130:141–155
99. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C (2001) Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. *Mol Biol Cell* 12:2730–2741
100. Strutz F, Zeisberg M (2006) Renal fibroblasts and myofibroblasts in chronic kidney disease. *J Am Soc Nephrol* 17:2992–2998
101. Zeisberg M, Strutz F, Muller GA (2001) Renal fibrosis: an update. *Curr Opin Nephrol Hypertens* 10:315–320
102. Han SW, Lee SE, Kim JH, Jeong HJ, Rha KH, Choi SK (1998) Does delayed operation for pediatric ureteropelvic junction obstruction cause histopathological changes? *J Urol* 160:984–988
103. Border WA, Noble NA (1998) Interactions of transforming growth factor- $\beta$  and angiotensin II in renal fibrosis. *Hypertension* 31: 181–188
104. Fern RJ, Yesko CM, Thornhill BA, Kim HS, Smithies O, Chevalier RL (1999) Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. *J Clin Invest* 103:39–46
105. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995) Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. *Kidney Int* 47:1285–1294
106. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, Klahr S (2001) Contributions of angiotensin II and tumor necrosis factor- $\alpha$  to the development of renal fibrosis. *Am J Physiol Ren Physiol* 280:F777–785
107. Fukuda K, Yoshitomi K, Yanagida T, Tokumoto M, Hirakata H (2001) Quantification of TGF- $\beta$  1 mRNA along rat nephron in obstructive nephropathy. *Am J Physiol Ren Physiol* 281:F513–521
108. Klahr S, Morrissey J (1998) Angiotensin II and gene expression in the kidney. *Am J Kidney Dis* 31:171–176
109. Chevalier RL, Forbes MS, Galarreta CI, Thornhill BA (2014) Responses of proximal tubular cells to injury in congenital renal disease: fight or flight. *Pediatr Nephrol* 29:537–541
110. Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA, Stern J, Jha S, Pigato J, Lemer ML, Poppas DP, Vaughan ED, Felsen D (2000) Antibody to transforming growth factor- $\beta$  ameliorates tubular apoptosis in unilateral ureteral obstruction. *Kidney Int* 58: 2301–2313
111. Manucha W, Oliveros L, Carrizo L, Seltzer A, Valles P (2004) Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. *Kidney Int* 65: 2091–2107
112. Jensen AM, Li C, Praetorius HA, Norregaard R, Frische S, Knepper MA, Nielsen S, Frokiaer J (2006) Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction. *Am J Physiol Ren Physiol* 291:F1021–1032
113. Kellner D, Chen J, Richardson I, Seshan SV, El Chaar M, Vaughan ED Jr, Poppas D, Felsen D (2006) Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. *J Urol* 176:806–812
114. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF- $\beta$  family signalling. *Nature* 425:577–584
115. Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ (2003) Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. *J Am Soc Nephrol* 14:1535–1548
116. Meng XM, Huang XR, Xiao J, Chen HY, Zhong X, Chung AC, Lan HY (2012) Diverse roles of TGF- $\beta$  receptor II in renal fibrosis and inflammation in vivo and in vitro. *J Pathol* 227:175–188
117. Galarreta CI, Thornhill BA, Forbes MS, Simpkins LN, Kim DK, Chevalier RL (2013) Transforming growth factor- $\beta$  1 receptor inhibition preserves glomerulotubular integrity during ureteral obstruction in adults but worsens injury in neonatal mice. *Am J Physiol Ren Physiol* 304:F481–490

118. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A (2003) Targeted disruption of TGF- $\beta$ 1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. *J Clin Invest* 112:1486–1494
119. Yang SP, Woolf AS, Quinn F, Winyard PJ (2001) Deregulation of renal transforming growth factor- $\beta$ 1 after experimental short-term ureteric obstruction in fetal sheep. *Am J Pathol* 159:109–117
120. Chung KH, Gomez RA, Chevalier RL (1995) Regulation of renal growth factors and clusterin by AT1 receptors during neonatal ureteral obstruction. *Am J Physiol* 268:F1117–1123
121. Pimentel JL, Sundell CL, Wang SS, Kopp JB, Montero A, Martinezmaldonado M (1995) Role of angiotensin-II in the expression and regulation of transforming growth-factor- $\beta$  in obstructive nephropathy. *Kidney Int* 48:1233–1246
122. Murer L, Benetti E, Centi S, Della Vella M, Artifoni L, Capizzi A, Zucchetto P, Del Prete D, Carasi C, Montini G, Rigamonti W, Zaccello G (2006) Clinical and molecular markers of chronic interstitial nephropathy in congenital unilateral ureteropelvic junction obstruction. *J Urol* 176:2668–2673
123. Forbes MS, Thornhill BA, Park MH, Chevalier RL (2007) Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. *Am J Pathol* 170:87–99
124. Sun D, Wang Y, Liu C, Zhou X, Li X, Xiao A (2012) Effects of nitric oxide on renal interstitial fibrosis in rats with unilateral ureteral obstruction. *Life Sci* 90:900–909
125. Chang B, Mathew R, Palmer LS, Valderrama E, Trachtman H (2002) Nitric oxide in obstructive uropathy: role of endothelial nitric oxide synthase. *J Urol* 168:1801–1804
126. Valles PG, Manucha W, Carrizo L, Vega Perugorria J, Seltzer A, Ruete C (2007) Renal caveolin-1 expression in children with unilateral ureteropelvic junction obstruction. *Pediatr Nephrol* 22:237–248
127. Nasu T, Kinomura M, Tanabe K, Yamasaki H, Htay SL, Saito D, Hinamoto N, Watatani H, Ujike H, Suzuki Y, Sugaya T, Sugiyama H, Sakai Y, Matsumoto K, Maeshima Y, Makino H (2012) Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. *Am J Physiol Ren Physiol* 302:F1616–1629
128. Miyajima A, Chen J, Poppas DP, Vaughan ED Jr, Felsen D (2001) Role of nitric oxide in renal tubular apoptosis of unilateral ureteral obstruction. *Kidney Int* 59:1290–1303
129. Mazzei L, Garcia IM, Cacciamani V, Benardon ME, Manucha W (2010) WT-1 mRNA expression is modulated by nitric oxide availability and Hsp70 interaction after neonatal unilateral ureteral obstruction. *Biocell* 34:121–132
130. Jensen AM, Bae EH, Fenton RA, Norregaard R, Nielsen S, Kim SW, Frokiaer J (2009) Angiotensin II regulates V2 receptor and pAQP2 during ureteral obstruction. *Am J Physiol Ren Physiol* 296:F127–134
131. Li C, Wang W, Kwon TH, Knepper MA, Nielsen S, Frokiaer J (2003) Altered expression of major renal Na transporters in rats with unilateral ureteral obstruction. *Am J Physiol Ren Physiol* 284:F155–166
132. Li C, Wang W, Kwon TH, Knepper MA, Nielsen S, Frokiaer J (2003) Altered expression of major renal Na transporters in rats with bilateral ureteral obstruction and release of obstruction. *Am J Physiol Ren Physiol* 285:F889–901
133. Li C, Klein JD, Wang W, Knepper MA, Nielsen S, Sands JM, Frokiaer J (2004) Altered expression of urea transporters in response to ureteral obstruction. *Am J Physiol Ren Physiol* 286:F1154–1162
134. Li C, Wang W, Knepper MA, Nielsen S, Frokiaer J (2003) Downregulation of renal aquaporins in response to unilateral ureteral obstruction. *Am J Physiol Ren Physiol* 284:F1066–1079
135. Shi Y, Li C, Thomsen K, Jorgensen TM, Knepper MA, Nielsen S, Djurhuus JC, Frokiaer J (2004) Neonatal ureteral obstruction alters expression of renal sodium transporters and aquaporin water channels. *Kidney Int* 66:203–215
136. Frokiaer J, Christensen BM, Marples D, Djurhuus JC, Jensen UB, Knepper MA, Nielsen S (1997) Downregulation of aquaporin-2 parallels changes in renal water excretion in unilateral ureteral obstruction. *Am J Physiol* 273:F213–223
137. Chen YC, Cadnapaphornchai MA, Schrier RW (2005) Clinical update on renal aquaporins. *Biol Cell* 97:357–371
138. Rubenwolf PC, Georgopoulos NT, Clements LA, Feather S, Holland P, Thomas DF, Southgate J (2009) Expression and localisation of aquaporin water channels in human urothelium in situ and in vitro. *Eur Urol* 56:1013–1023
139. Spector DA, Wade JB, Dillow R, Steplock DA, Weinman EJ (2002) Expression, localization, and regulation of aquaporin-1 to -3 in rat urothelia. *Am J Physiol Ren Physiol* 282:F1034–1042
140. Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi Y, Engel A, Nielsen S (2002) Aquaporin water channels—from atomic structure to clinical medicine. *J Physiol* 542:3–16
141. Wen JG, Li ZZ, Zhang H, Wang Y, Wang G, Wang Q, Nielsen S, Djurhuus JC, Frokiaer J (2009) Expression of renal aquaporins is down-regulated in children with congenital hydronephrosis. *Scand J Urol Nephrol* 43:486–493
142. Frokiaer J, Marples D, Knepper MA, Nielsen S (1996) Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. *Am J Physiol* 270:F657–668
143. Li C, Wang W, Kwon TH, Isikay L, Wen JG, Marples D, Djurhuus JC, Stockwell A, Knepper MA, Nielsen S, Frokiaer J (2001) Downregulation of AQP1, -2, and -3 after ureteral obstruction is associated with a long-term urine-concentrating defect. *Am J Physiol Ren Physiol* 281:F163–171
144. Ishidoya S, Morrissey J, McCracken R, Klahr S (1996) Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. *Kidney Int* 49:1110–1119
145. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S (1994) Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. *Kidney Int* 45:1637–1647
146. Klahr S, Morrissey J (2002) Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. *Kidney Int Suppl* 82:S23–26
147. Chen CO, Park MH, Forbes MS, Thornhill BA, Kiley SC, Yoo KH, Chevalier RL (2007) Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat. *Am J Physiol Ren Physiol* 292:F946–955
148. Coleman CM, Minor JJ, Burt LE, Thornhill BA, Forbes MS, Chevalier RL (2007) Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. *Am J Physiol Ren Physiol* 293:F262–268
149. Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C (2012) Losartan and enalapril are comparable in reducing proteinuria in children. *Kidney Int* 82:819–826
150. ItalKid Project, Ardissino G, Vigano S, Testa S, Dacco V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, La Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM (2007) No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy—report from the ItalKid Project database. *Nephrol Dial Transplant* 22:2525–2530
151. Hari P, Sahu J, Sinha A, Pandey RM, Bal CS, Bagga A (2013) Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial. *Indian Pediatr* 50:923–928
152. Moriyama T, Kawada N, Nagatoya K, Takeji M, Horio M, Ando A, Imai E, Hori M (2001) Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. *Kidney Int* 59:2095–2103
153. Mizuguchi Y, Miyajima A, Kosaka T, Asano T, Asano T, Hayakawa M (2004) Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. *J Urol* 172:2456–2459

154. Rodriguez-Pena AB, Fuentes-Calvo I, Docherty NG, Arevalo M, Grande MT, Eleno N, Perez-Barriocanal F, Lopez-Novoa JM (2014) Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy. *Biomed Res Int* 2014:124902
155. Jasinska M, Owczarek J, Orszulak-Michalak D (2007) Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. *Pharmacol Rep* 59:483–499
156. Kamdar C, Chou SY, Mooppan UM, Kim H, Gulmi FA (2010) Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction. *Urology* 75:853–857
157. Danilovic A, Lopes RI, Sanches TR, Shimizu MH, Oshiro FM, Andrade L, Denes FT, Seguro AC (2012) Atorvastatin prevents the downregulation of aquaporin-2 receptor after bilateral ureteral obstruction and protects renal function in a rat model. *Urology* 80(485):e415–420
158. Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. *Acta Cardiol Sin* 32:631–639
159. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA (2014) Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. *JAMA* 312:1055–1057
160. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK (2006) IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. *Kidney Int* 70:1234–1243
161. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, Dezube BJ, Hsu FJ, Reiss M, Berzofsky JA (2008) Phase I/II study of GC1008: A human anti-transforming growth factor-beta (TGF $\beta$ ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. *J Clin Oncol* 26[Suppl]: abstr 9028
162. Kamata M, Hosono K, Fujita T, Kamata K, Majima M (2015) Role of cyclooxygenase-2 in the development of interstitial fibrosis in kidneys following unilateral ureteral obstruction in mice. *Biomed Pharmacother* 70:174–180
163. Pediatric Rheumatology Collaborative Study Group, Sobel RE, Lovell DJ, Brunner HI, Weiss JE, Morris PW, Gottlieb BS, Chalom EC, Jung LK, Onel KB, Petiniot L, Goldsmith DP, Nanda K, Shishov M, Abramsky S, Young JP, Giannini EH (2014) Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry. *Pediatr Rheumatol Online J* 12:29
164. Shiva S (2013) Nitrite: a physiological store of nitric oxide and modulator of mitochondrial function. *Redox Biol* 1:40–44
165. Tripatara P, Patel NS, Webb A, Rathod K, Lecomte FM, Mazzon E, Cuzzocrea S, Yaqoob MM, Ahluwalia A, Thiemermann C (2007) Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. *J Am Soc Nephrol* 18:570–580
166. Gilchrist M, Winyard PG, Benjamin N (2010) Dietary nitrate—good or bad? *Nitric Oxide* 22:104–109
167. Yuan Y, Zhang F, Wu J, Shao C, Gao Y (2015) Urinary candidate biomarker discovery in a rat unilateral ureteral obstruction model. *Sci Rep* 5:9314
168. Taha MA, Shokeir AA, Osman HG, Abd El-Aziz Ael A, Farahat SE (2007) Obstructed versus dilated nonobstructed kidneys in children with congenital ureteropelvic junction narrowing: role of urinary tubular enzymes. *J Urol* 178:640–646
169. Taranta-Janusz K, Wasilewska A, Debek W, Filonowicz R, Michaluk-Skutnik J (2013) Urinary angiotensinogen as a novel marker of obstructive nephropathy in children. *Acta Paediatr* 102: e429–433
170. Bartoli F, Penza R, Aceto G, Niglio F, D'Addato O, Pastore V, Campanella V, Magaldi S, Lasalandra C, Di Bitonto G, Gesualdo L (2011) Urinary epidermal growth factor, monocyte chemotactic protein-1, and beta2-microglobulin in children with ureteropelvic junction obstruction. *J Pediatr Surg* 46:530–536
171. Madsen MG, Norregaard R, Palmfeldt J, Olsen LH, Frokiaer J, Jorgensen TM (2012) Urinary NGAL, cystatin C, beta2-microglobulin, and osteopontin significance in hydronephrotic children. *Pediatr Nephrol* 27:2099–2106
172. Atar A, Oktar T, Kucukgergin C, Kalelioglu I, Seckin S, Ander H, Ziyhan O, Kadioglu TC (2015) The roles of serum and urinary carbohydrate antigen 19–9 in the management of patients with antenatal hydronephrosis. *J Pediatr Urol* 11(133):e1–5
173. Kajbafzadeh AM, Elmi A, Talab SS, Emami H, Esfahani SA, Saeedi P (2010) Urinary and serum carbohydrate antigen 19–9 as a biomarker in ureteropelvic junction obstruction in children. *J Urol* 183:2353–2360
174. Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Paradies G, Caldarulo E, Infante B, Schena FP (2000) MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. *Kidney Int* 58:182–192
175. Madsen MG, Norregaard R, Palmfeldt J, Olsen LH, Frokiaer J, Jorgensen TM (2013) Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis. *J Pediatr Urol* 9:838–845
176. Taha MA, Shokeir AA, Osman HG, Abd El-Aziz Ael A, Farahat SE (2007) Pelvi-ureteric junction obstruction in children: the role of urinary transforming growth factor-beta and epidermal growth factor. *BJU Int* 99:899–903
177. Taha MA, Shokeir AA, Osman HG, Abd el-Aziz Ael A, Farahat SE (2007) Diagnosis of ureteropelvic junction obstruction in children: role of endothelin-1 in voided urine. *Urology* 69:560–564, discussion 564–565
178. Li Z, Liu X, Liu S, Gu C, Tian F, Wen J (2012) Urinary heme oxygenase-1 in children with congenital hydronephrosis due to ureteropelvic junction obstruction. *Biomarkers* 17:471–476
179. Wasilewska A, Taranta-Janusz K, Debek W, Zoch-Zwierz W, Kuroczycka-Saniutycz E (2011) KIM-1 and NGAL: new markers of obstructive nephropathy. *Pediatr Nephrol* 26:579–586
180. Taranta-Janusz K, Wasilewska A, Debek W, Waszkiewicz-Stojda M (2012) Urinary cytokine profiles in unilateral congenital hydronephrosis. *Pediatr Nephrol* 27:2107–2113
181. Cost NG, Noh PH, Devarajan P, Ivancic V, Reddy PP, Minevich E, Bennett M, Haffner C, Schulte M, DeFoor WR Jr (2013) Urinary NGAL levels correlate with differential renal function in patients with ureteropelvic junction obstruction undergoing pyeloplasty. *J Urol* 190[4 Suppl]:1462–1467
182. Almodhen F, Loutochin O, Capolicchio JP, Jednak R, El-Sherbiny M (2009) The role of bladder urine transforming growth factor-beta1 concentrations in diagnosis and management of unilateral prenatal hydronephrosis. *J Urol* 182:292–298, discussion 298
183. Madsen MG, Norregaard R, Frokiaer J, Jorgensen TM (2011) Urinary biomarkers in prenatally diagnosed unilateral hydronephrosis. *J Pediatr Urol* 7:105–112
184. Papachristou F, Pavlaki A, Printza N (2014) Urinary and serum biomarkers in ureteropelvic junction obstruction: a systematic review. *Biomarkers* 19:531–540
185. Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, Bouissou F, Bascands JL, Schanstra JP (2006) Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. *Nat Med* 12:398–400
186. Drube J, Zurbig P, Schiffer E, Lau E, Ure B, Gluer S, Kirschstein M, Pape L, Decramer S, Bascands JL, Schanstra JP, Mischak H, Ehrlich JH (2010) Urinary proteome analysis identifies infants but not older children requiring pyeloplasty. *Pediatr Nephrol* 25:1673–1678